人血浆中Neu5Ac和neu5,9ac2浓度升高:心血管疾病的潜在生物标志物

IF 2.7 4区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY
Glycoconjugate Journal Pub Date : 2023-12-01 Epub Date: 2023-11-22 DOI:10.1007/s10719-023-10138-3
Jack Cheeseman, Concepcion Badia, Georgia Elgood-Hunt, Richard A Gardner, Duong N Trinh, Marco P Monopoli, Gunter Kuhnle, Daniel I R Spencer, Helen M I Osborn
{"title":"人血浆中Neu5Ac和neu5,9ac2浓度升高:心血管疾病的潜在生物标志物","authors":"Jack Cheeseman, Concepcion Badia, Georgia Elgood-Hunt, Richard A Gardner, Duong N Trinh, Marco P Monopoli, Gunter Kuhnle, Daniel I R Spencer, Helen M I Osborn","doi":"10.1007/s10719-023-10138-3","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular disease (CVD) is a group of health conditions affecting the heart and vascular system with very high prevalence and mortality rates. The presence of CVD is characterised by high levels of inflammation which have previously been associated with increased plasma concentrations of N-acetyl neuraminic acid (Neu5Ac). While Neu5Ac has been studied in the context of CVD, Neu5,9Ac<sub>2</sub> has not, despite being the second most abundant sialic acid in human plasma. A small-scale pilot study of thirty plasma samples from patients with diagnosed CVD, and thirty age and sex-matched healthy controls, was designed to gain insight into sialic acids as biomarkers for CVD and potential future areas of study. Each sample was assayed for Neu5Ac and Neu5,9Ac<sub>2</sub> concentrations. Mean Neu5Ac and Neu5,9Ac<sub>2</sub> concentrations were significantly elevated in patients with CVD compared to healthy controls (Neu5Ac: P < 0.001; Neu5,9Ac<sub>2</sub>: P < 0.04). Receiver operator curve (ROC) analysis indicated that both Neu5Ac and Neu5,9Ac<sub>2</sub> have reasonable predictive power for the presence of CVD (Neu5Ac AUC: 0.86; Neu5,9Ac<sub>2</sub> AUC: 0.71). However, while Neu5Ac had both good sensitivity (0.82) and specificity (0.81), Neu5,9Ac<sub>2</sub> had equivalent specificity (0.81) but very poor sensitivity (0.44). A combination marker of Neu5Ac + Neu5,9Ac<sub>2</sub> showed improvement over Neu5Ac alone in terms of predictive power (AUC: 0.93), sensitivity (0.87), and specificity (0.90). Comparison to a known inflammatory marker, high sensitivity c-reactive protein (hs-CRP: P-value: NS, ROC:0.50) was carried out, showing that both Neu5Ac and Neu5,9Ac<sub>2</sub> outperformed this marker. Further to this, hs-CRP values were combined with the three different sialic acid markers to determine any effect on the AUC values. A slight improvement in AUC was noted for each of the combinations, with Neu5Ac + Neu5,9Ac<sub>2</sub> + hs-CRP giving the best AUC of 0.97 overall. Thus, Neu5Ac would appear to offer good potential as a predictive marker for the presence of CVD, which the addition of Neu5,9Ac<sub>2</sub> predictive power improves, with further improvement seen by the addition of hs-CRP.</p>","PeriodicalId":12762,"journal":{"name":"Glycoconjugate Journal","volume":" ","pages":"645-654"},"PeriodicalIF":2.7000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10788320/pdf/","citationCount":"0","resultStr":"{\"title\":\"Elevated concentrations of Neu5Ac and Neu5,9Ac<sub>2</sub> in human plasma: potential biomarkers of cardiovascular disease.\",\"authors\":\"Jack Cheeseman, Concepcion Badia, Georgia Elgood-Hunt, Richard A Gardner, Duong N Trinh, Marco P Monopoli, Gunter Kuhnle, Daniel I R Spencer, Helen M I Osborn\",\"doi\":\"10.1007/s10719-023-10138-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cardiovascular disease (CVD) is a group of health conditions affecting the heart and vascular system with very high prevalence and mortality rates. The presence of CVD is characterised by high levels of inflammation which have previously been associated with increased plasma concentrations of N-acetyl neuraminic acid (Neu5Ac). While Neu5Ac has been studied in the context of CVD, Neu5,9Ac<sub>2</sub> has not, despite being the second most abundant sialic acid in human plasma. A small-scale pilot study of thirty plasma samples from patients with diagnosed CVD, and thirty age and sex-matched healthy controls, was designed to gain insight into sialic acids as biomarkers for CVD and potential future areas of study. Each sample was assayed for Neu5Ac and Neu5,9Ac<sub>2</sub> concentrations. Mean Neu5Ac and Neu5,9Ac<sub>2</sub> concentrations were significantly elevated in patients with CVD compared to healthy controls (Neu5Ac: P < 0.001; Neu5,9Ac<sub>2</sub>: P < 0.04). Receiver operator curve (ROC) analysis indicated that both Neu5Ac and Neu5,9Ac<sub>2</sub> have reasonable predictive power for the presence of CVD (Neu5Ac AUC: 0.86; Neu5,9Ac<sub>2</sub> AUC: 0.71). However, while Neu5Ac had both good sensitivity (0.82) and specificity (0.81), Neu5,9Ac<sub>2</sub> had equivalent specificity (0.81) but very poor sensitivity (0.44). A combination marker of Neu5Ac + Neu5,9Ac<sub>2</sub> showed improvement over Neu5Ac alone in terms of predictive power (AUC: 0.93), sensitivity (0.87), and specificity (0.90). Comparison to a known inflammatory marker, high sensitivity c-reactive protein (hs-CRP: P-value: NS, ROC:0.50) was carried out, showing that both Neu5Ac and Neu5,9Ac<sub>2</sub> outperformed this marker. Further to this, hs-CRP values were combined with the three different sialic acid markers to determine any effect on the AUC values. A slight improvement in AUC was noted for each of the combinations, with Neu5Ac + Neu5,9Ac<sub>2</sub> + hs-CRP giving the best AUC of 0.97 overall. Thus, Neu5Ac would appear to offer good potential as a predictive marker for the presence of CVD, which the addition of Neu5,9Ac<sub>2</sub> predictive power improves, with further improvement seen by the addition of hs-CRP.</p>\",\"PeriodicalId\":12762,\"journal\":{\"name\":\"Glycoconjugate Journal\",\"volume\":\" \",\"pages\":\"645-654\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10788320/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Glycoconjugate Journal\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1007/s10719-023-10138-3\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Glycoconjugate Journal","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s10719-023-10138-3","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

心血管疾病(CVD)是一组影响心脏和血管系统的健康状况,具有非常高的患病率和死亡率。CVD的特点是高水平的炎症,这与血浆n -乙酰神经氨酸(Neu5Ac)浓度升高有关。虽然Neu5Ac已经在CVD的背景下进行了研究,但neu59ac2虽然是人类血浆中第二丰富的唾液酸,但尚未进行研究。一项小规模的试点研究,从诊断为CVD的患者和30名年龄和性别匹配的健康对照中抽取了30份血浆样本,旨在深入了解唾液酸作为CVD的生物标志物和潜在的未来研究领域。每个样品检测Neu5Ac和neu5,9ac2浓度。与健康对照组相比,CVD患者的Neu5Ac和neu5,9ac2平均浓度显著升高(Neu5Ac: p2: p2对CVD存在有合理的预测能力(Neu5Ac AUC: 0.86;Neu5,9Ac2 AUC: 0.71)。然而,Neu5Ac具有良好的敏感性(0.82)和特异性(0.81),而neu5,9ac2具有相同的特异性(0.81),但敏感性很差(0.44)。Neu5Ac + neu5,9ac2的联合标记在预测能力(AUC: 0.93)、敏感性(0.87)和特异性(0.90)方面优于Neu5Ac单独使用。与已知炎症标志物高敏感性c反应蛋白(hs-CRP: p值:NS, ROC:0.50)进行比较,表明Neu5Ac和neu5,9ac2的表现都优于该标志物。此外,将hs-CRP值与三种不同的唾液酸标记物结合,以确定对AUC值的影响。每种组合的AUC都略有改善,Neu5Ac + Neu5,9Ac2 + hs-CRP的AUC最好,为0.97。因此,Neu5Ac作为CVD存在的预测标记物似乎具有良好的潜力,加入neu5,9ac2可提高CVD的预测能力,加入hs-CRP可进一步提高CVD的预测能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Elevated concentrations of Neu5Ac and Neu5,9Ac<sub>2</sub> in human plasma: potential biomarkers of cardiovascular disease.

Elevated concentrations of Neu5Ac and Neu5,9Ac2 in human plasma: potential biomarkers of cardiovascular disease.

Cardiovascular disease (CVD) is a group of health conditions affecting the heart and vascular system with very high prevalence and mortality rates. The presence of CVD is characterised by high levels of inflammation which have previously been associated with increased plasma concentrations of N-acetyl neuraminic acid (Neu5Ac). While Neu5Ac has been studied in the context of CVD, Neu5,9Ac2 has not, despite being the second most abundant sialic acid in human plasma. A small-scale pilot study of thirty plasma samples from patients with diagnosed CVD, and thirty age and sex-matched healthy controls, was designed to gain insight into sialic acids as biomarkers for CVD and potential future areas of study. Each sample was assayed for Neu5Ac and Neu5,9Ac2 concentrations. Mean Neu5Ac and Neu5,9Ac2 concentrations were significantly elevated in patients with CVD compared to healthy controls (Neu5Ac: P < 0.001; Neu5,9Ac2: P < 0.04). Receiver operator curve (ROC) analysis indicated that both Neu5Ac and Neu5,9Ac2 have reasonable predictive power for the presence of CVD (Neu5Ac AUC: 0.86; Neu5,9Ac2 AUC: 0.71). However, while Neu5Ac had both good sensitivity (0.82) and specificity (0.81), Neu5,9Ac2 had equivalent specificity (0.81) but very poor sensitivity (0.44). A combination marker of Neu5Ac + Neu5,9Ac2 showed improvement over Neu5Ac alone in terms of predictive power (AUC: 0.93), sensitivity (0.87), and specificity (0.90). Comparison to a known inflammatory marker, high sensitivity c-reactive protein (hs-CRP: P-value: NS, ROC:0.50) was carried out, showing that both Neu5Ac and Neu5,9Ac2 outperformed this marker. Further to this, hs-CRP values were combined with the three different sialic acid markers to determine any effect on the AUC values. A slight improvement in AUC was noted for each of the combinations, with Neu5Ac + Neu5,9Ac2 + hs-CRP giving the best AUC of 0.97 overall. Thus, Neu5Ac would appear to offer good potential as a predictive marker for the presence of CVD, which the addition of Neu5,9Ac2 predictive power improves, with further improvement seen by the addition of hs-CRP.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Glycoconjugate Journal
Glycoconjugate Journal 生物-生化与分子生物学
CiteScore
6.00
自引率
3.30%
发文量
63
审稿时长
1 months
期刊介绍: Glycoconjugate Journal publishes articles and reviews on all areas concerned with: function, composition, structure, biosynthesis, degradation, interactions, recognition and chemo-enzymatic synthesis of glycoconjugates (glycoproteins, glycolipids, oligosaccharides, polysaccharides and proteoglycans), biochemistry, molecular biology, biotechnology, immunology and cell biology of glycoconjugates, aspects related to disease processes (immunological, inflammatory, arthritic infections, metabolic disorders, malignancy, neurological disorders), structural and functional glycomics, glycoimmunology, glycovaccines, organic synthesis of glycoconjugates and the development of methodologies if biologically relevant, glycosylation changes in disease if focused on either the discovery of a novel disease marker or the improved understanding of some basic pathological mechanism, articles on the effects of toxicological agents (alcohol, tobacco, narcotics, environmental agents) on glycosylation, and the use of glycotherapeutics. Glycoconjugate Journal is the official journal of the International Glycoconjugate Organization, which is responsible for organizing the biennial International Symposia on Glycoconjugates.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信